ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.053,75
-1,02%
S&P 500
5.872,16
-2,95%
Dow Jones
42.326,87
-2,58%
Euro vs US Dollar
1,04053
0,53%
Bitcoin
102.246,95
2,18%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) News

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KPTI
DatumZeitQuelleÜberschriftSymbolFirma
16/12/202422h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
09/12/202414h00PR Newswire (US)Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202422h35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/12/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
03/12/202413h00PR Newswire (US)Karyopharm Therapeutics Provides Endometrial Cancer Program UpdateNASDAQ:KPTIKaryopharm Therapeutics Inc
02/12/202413h00PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
25/11/202413h00PR Newswire (US)Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
22/11/202422h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
20/11/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
20/11/202422h05PR Newswire (US)Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNASDAQ:KPTIKaryopharm Therapeutics Inc
14/11/202422h22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/11/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
06/11/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202414h02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202413h47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202413h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202413h30PR Newswire (US)Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
01/11/202421h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202413h00PR Newswire (US)Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202412h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202412h30PR Newswire (US)Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202421h30PR Newswire (US)Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
01/10/202422h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
17/09/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
05/09/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/09/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/09/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/09/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/09/202422h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Kürzlich von Ihnen besucht

LSE
39XK
Gran.04 2 1a1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten